Feeds › Ownership stakes (13D / 13G)
Ownership stakes (13D / 13G)
Investors who own more than 5% of a company, from activists (13D) to passive holders (13G).
About this data
- What it is
- An investor who owns more than 5% of a public company must say so. Investors who may try to influence the company, such as activists, file the longer Schedule 13D; passive holders file the shorter Schedule 13G.
- Who files it
- The investor, within days of crossing 5%, and again whenever the stake changes materially.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- 13G filings are far more common than 13D. A 13D usually means the investor intends to push for changes, so it tends to get more attention.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Filings per day, last 30 days
13D (activist) 13G (passive)
Latest ownership filings
Showing: ticker KLRS
| Filed | ScheduleBoth report a stake of more than 5%. A 13D is filed by investors who may try to influence the company, such as activists; a 13G by passive holders. | Company | Investor | Shares | % of shares | Filing |
|---|---|---|---|---|---|---|
| Oct 26, 2026 | SCHEDULE 13G | KLRS Kalaris Therapeutics, Inc. | Matthew D. Perry | 1.36M | 5.7% | SCHEDULE 13G ↗ |
| Oct 26, 2026 | SCHEDULE 13G | KLRS Kalaris Therapeutics, Inc. | Coastlands Capital LLC | 1.36M | 5.7% | SCHEDULE 13G ↗ |
| Oct 26, 2026 | SCHEDULE 13G | KLRS Kalaris Therapeutics, Inc. | Coastlands Capital GP LLC | 1.36M | 5.7% | SCHEDULE 13G ↗ |
| Oct 26, 2026 | SCHEDULE 13G | KLRS Kalaris Therapeutics, Inc. | Coastlands Capital Partners LP | 1.36M | 5.7% | SCHEDULE 13G ↗ |
| Oct 26, 2026 | SCHEDULE 13G | KLRS Kalaris Therapeutics, Inc. | Coastlands Capital LP | 1.36M | 5.7% | SCHEDULE 13G ↗ |
| May 22, 2026 | SCHEDULE 13D/A (amended) | KLRS Kalaris Therapeutics, Inc. | Srinivas Akkaraju | 12.90M | 54.2% | SCHEDULE 13D/A ↗ |
| May 22, 2026 | SCHEDULE 13D/A (amended) | KLRS Kalaris Therapeutics, Inc. | Samsara Opportunity Fund GP, LLC | 2.22M | 9.3% | SCHEDULE 13D/A ↗ |
| May 22, 2026 | SCHEDULE 13D/A (amended) | KLRS Kalaris Therapeutics, Inc. | Samsara Opportunity Fund, L.P. | 2.22M | 9.3% | SCHEDULE 13D/A ↗ |
| May 22, 2026 | SCHEDULE 13D/A (amended) | KLRS Kalaris Therapeutics, Inc. | Samsara BioCapital GP, LLC | 10.67M | 44.9% | SCHEDULE 13D/A ↗ |
| May 22, 2026 | SCHEDULE 13D/A (amended) | KLRS Kalaris Therapeutics, Inc. | Samsara BioCapital, L.P. | 10.66M | 44.8% | SCHEDULE 13D/A ↗ |
| Feb 17, 2026 | SCHEDULE 13D/A (amended) | KLRS Kalaris Therapeutics, Inc. | Srinivas Akkaraju | 12.95M | 56.5% | SCHEDULE 13D/A ↗ |
| Feb 17, 2026 | SCHEDULE 13D/A (amended) | KLRS Kalaris Therapeutics, Inc. | Samsara Opportunity Fund GP, LLC | 1.98M | 8.6% | SCHEDULE 13D/A ↗ |
| Feb 17, 2026 | SCHEDULE 13D/A (amended) | KLRS Kalaris Therapeutics, Inc. | Samsara Opportunity Fund, L.P. | 1.98M | 8.6% | SCHEDULE 13D/A ↗ |
| Feb 17, 2026 | SCHEDULE 13D/A (amended) | KLRS Kalaris Therapeutics, Inc. | Samsara BioCapital GP, LLC | 10.97M | 47.9% | SCHEDULE 13D/A ↗ |
| Feb 17, 2026 | SCHEDULE 13D/A (amended) | KLRS Kalaris Therapeutics, Inc. | Samsara BioCapital, L.P. | 10.97M | 47.9% | SCHEDULE 13D/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G | KLRS Kalaris Therapeutics, Inc. | Roderick Wong | 1.30M | 5.7% | SCHEDULE 13G ↗ |
| Feb 17, 2026 | SCHEDULE 13G | KLRS Kalaris Therapeutics, Inc. | RTW Investments, LP | 1.30M | 5.7% | SCHEDULE 13G ↗ |
| Dec 22, 2025 | SCHEDULE 13D/A (amended) | KLRS Kalaris Therapeutics, Inc. | Srinivas Akkaraju | 12.95M | 56.5% | SCHEDULE 13D/A ↗ |
| Dec 22, 2025 | SCHEDULE 13D/A (amended) | KLRS Kalaris Therapeutics, Inc. | Samsara Opportunity Fund GP, LLC | 1.50M | 6.5% | SCHEDULE 13D/A ↗ |
| Dec 22, 2025 | SCHEDULE 13D/A (amended) | KLRS Kalaris Therapeutics, Inc. | Samsara Opportunity Fund, L.P. | 1.50M | 6.5% | SCHEDULE 13D/A ↗ |
| Dec 22, 2025 | SCHEDULE 13D/A (amended) | KLRS Kalaris Therapeutics, Inc. | Samsara BioCapital GP, LLC | 11.45M | 50.0% | SCHEDULE 13D/A ↗ |
| Dec 22, 2025 | SCHEDULE 13D/A (amended) | KLRS Kalaris Therapeutics, Inc. | Samsara BioCapital, L.P. | 11.45M | 50.0% | SCHEDULE 13D/A ↗ |
| Jul 29, 2025 | SCHEDULE 13G/A (amended) | KLRS Kalaris Therapeutics, Inc. | Raymond Debbane | 282,586 | 1.5% | SCHEDULE 13G/A ↗ |
| Jul 29, 2025 | SCHEDULE 13G/A (amended) | KLRS Kalaris Therapeutics, Inc. | Siren, L.L.C. | 282,586 | 1.5% | SCHEDULE 13G/A ↗ |
| Jul 29, 2025 | SCHEDULE 13G/A (amended) | KLRS Kalaris Therapeutics, Inc. | Invus Global Management, LLC | 282,586 | 1.5% | SCHEDULE 13G/A ↗ |
| Jul 29, 2025 | SCHEDULE 13G/A (amended) | KLRS Kalaris Therapeutics, Inc. | Invus Public Equities Advisors, LLC | 282,586 | 1.5% | SCHEDULE 13G/A ↗ |
| Jul 29, 2025 | SCHEDULE 13G/A (amended) | KLRS Kalaris Therapeutics, Inc. | Invus Public Equities, L.P. | 282,586 | 1.5% | SCHEDULE 13G/A ↗ |
| May 15, 2025 | SCHEDULE 13G/A (amended) | KLRS Kalaris Therapeutics, Inc. | EcoR1 Capital Fund Qualified, L.P. | 191,242 | 1.0% | SCHEDULE 13G/A ↗ |
| May 15, 2025 | SCHEDULE 13G/A (amended) | KLRS Kalaris Therapeutics, Inc. | Oleg Nodelman | 201,718 | 1.1% | SCHEDULE 13G/A ↗ |
| May 15, 2025 | SCHEDULE 13G/A (amended) | KLRS Kalaris Therapeutics, Inc. | EcoR1 Capital, LLC | 201,718 | 1.1% | SCHEDULE 13G/A ↗ |
| Mar 25, 2025 | SCHEDULE 13D | KLRS Kalaris Therapeutics, Inc. | Srinivas Akkaraju | 11.45M | 61.2% | SCHEDULE 13D ↗ |
| Mar 25, 2025 | SCHEDULE 13D | KLRS Kalaris Therapeutics, Inc. | Samsara BioCapital GP, LLC | 11.45M | 61.2% | SCHEDULE 13D ↗ |
| Mar 25, 2025 | SCHEDULE 13D | KLRS Kalaris Therapeutics, Inc. | Samsara BioCapital, L.P. | 11.45M | 61.2% | SCHEDULE 13D ↗ |
| Mar 20, 2025 | SCHEDULE 13G/A (amended) | KLRS Kalaris Therapeutics, Inc. | Gilead Sciences, Inc. | 723,273 | 3.9% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | KLRS Kalaris Therapeutics, Inc. | EcoR1 Capital Fund Qualified, L.P. | 385,705 | 7.7% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | KLRS Kalaris Therapeutics, Inc. | Oleg Nodelman | 408,688 | 8.1% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | KLRS Kalaris Therapeutics, Inc. | EcoR1 Capital, LLC | 408,688 | 8.1% | SCHEDULE 13G/A ↗ |
37 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 8:19 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances